Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

被引：8

作者：

Kuchnio, Anna ^{[1
]}

Samakai, Elsie ^{[2
]}

Hug, Eva ^{[3
]}

Balmana, Meritxell ^{[3
]}

Janssen, Lut ^{[1
]}

Amorim, Ricardo ^{[1
]}

Cornelissen, Ivo ^{[1
]}

Majoros, Andrea ^{[3
]}

Broux, Michael ^{[1
]}

Taneja, Isha ^{[2
]}

Torti, Vince ^{[4
]}

Agic, Azra ^{[3
]}

Moritsch, Stefan ^{[3
]}

Benedetti, Filippo ^{[3
]}

Rosebrock, Felix ^{[3
]}

Packman, Kathryn ^{[5
]}

Arts, Janine ^{[6
]}

Patel, Sonal ^{[7
]}

Lomas, Oliver Christopher ^{[8
]}

Deyoung, M. Phillip ^{[2
]}

Zagrijtschuk, Oleh ^{[3
]}

Elsayed, Yusri ^{[9
]}

Constantinescu, Stefan ^{[10
,11
,12
,13
]}

Kralovics, Robert ^{[14
]}

Philippar, Ulrike ^{[15
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Janssen Res & Dev, Spring House, PA USA

[3] MyeloPro Diagnost & Res GmbH, Vienna, Austria

[4] Janssen Res & Dev, La Jolla, CA USA

[5] Janssen Res & Dev LLC, Cambridge, MA USA

[6] Janssen Sci Innovat Oncol, Beerse, Belgium

[7] Janssen Sci Innovat Oncol, London, England

[8] Janssen Res & Dev, High Wycombe, England

[9] Janssen Res & Dev LLC, Spring House, PA USA

[10] Ludwig Inst Canc Res, Brussels, Belgium

[11] UCLouvain, Duve Inst, Brussels, Belgium

[12] Wel Res Inst, Welbio Dept, Wavre, Belgium

[13] Univ Oxford, Nuffield Dept Med, Ludwig Canc Res Oxford, Oxford, England

[14] Med Univ Vienna, Vienna, Austria

[15] Janssen Res & Dev LLC, Beerse, Belgium

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173430

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 44 条

[11] Target expression, preclinical activity and mechanism of action of EM801: a novel first-in-class IgG-based BCMA T-cell bispecific antibody for the treatment of multiple myeloma
Seckinger, A.
Delgado, J. A.
Moreno, L.
Neuber, B.
Grab, A. L.
Lipp, S.
Merino, J.
Vu, M. D.
Strein, K.
Prosper, F.
Hundemer, M.
San Miguel, J.
Hose, D.
Paiva, B.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 207 - 208
[12] Anti-GPC3 TRAB, a first-in-class T cell-redirecting bispecific antibody targeting glypican-3 with potent in vitro and in vivo antitumor efficacy against solid tumors
Kinoshita, Yasuko
Ishiguro, Takahiro
Sano, Yuji
Azuma, Yumiko
Tsunenari, Toshiaki
Ono, Natsuki
Kayukawa, Yoko
Ueda, Otoya
Wada, Naoko A.
Hino, Hiroshi
Jishage, Koichi
Shiraiwa, Hirotake
Kamata-Sakurai, Mika
Nezu, Junichi
Endo, Mika
CANCER RESEARCH, 2016, 76
[13] New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
Moreno, Laura
Zabaleta, Aintzane
Alignani, Diego
Lasa, Marta
Maiso, Patricia
Jelinek, Tomas
Segura, Victor
Delgado, Jose Antonio
Rodriguez-Otero, Paula
Prosper, Felipe
Strein, Klaus
Vu, Minh Diem
Miguel, Jesus San
Paiva, Bruno
BLOOD, 2016, 128 (22)
[14] LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies
Yang, Wei
Burns, Colleen
Lindquist, Kevin
Dobkin, Julie
Shin, Hee Rae
Nguyen, Cindy
Huang, Xiaodong
Helms, Whitney
Arce, Nicholas
Mak, Yvonne
Au, Audrey
Abouzeid, Abraham
Witek, Marta
Leow, Ching Ching
Gong, Xueqian
Srinivasan, Mohan
Park, Joshua I.
Driscoll, Kyla
Hass, Andrew
Holmgaard, Rikke
Duramad, Omar
Bedard, Kristin
BLOOD, 2024, 144 : 2785 - 2786
[15] Therapy of cutaneous T-cell Lymphomas Mycosis fungoides and Sezary Syndrome Mogamulizumab: first-in-class Anti-CCR4 Monoclonal Antibody
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[16] JNJ-79032421 is a novel membrane restricted mesothelin targeting T-cell engaging bispecific antibody for treatment of mesothelin-positive cancers
Smans, K.
Nesspor, T.
De Breuker, S.
Van Heerde, E.
Valckx, A.
Van Slycken, N.
Sproesser, K.
Mattson, B.
Packman, K.
Fisher, J.
Mazzanti, N.
Petley, T.
Chan, W.
Del Rosario, B.
Tun, L.
Lorenzi, M.
Moores, S.
Clawson, J.
Laquerre, S.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S59 - S59
[17] BOXR1030: A first-in-class CAR T-cell therapy co-expressing GOT2 enhances T-cell metabolic function for the treatment of GPC3-positive solid tumors
Choi, Eugene
Whiteman, Kathleen
Pai, Tapasya
Hickman, Taylor
Johnson, Tyler
Friedman, Taylor
Parikh, Avani
Gilbert, Madaline
Shen, Binzhang
Weiss, Glen J.
Ettenberg, Seth
McGinness, Kathleen E.
Motz, Greg
CANCER RESEARCH, 2020, 80 (16)
[18] Differential exhaustion on cytokine release (DECREASE) by ERY974, a novel T-cell-redirecting antibody targeting glypican-3: A new type of T-cell exhaustion
Hoshino, Mayumi
Sano, Yuji
Kinoshita, Yasuko
Azuma, Yumiko
Tsunenari, Toshiaki
Kayukawa, Yoko
Noguchi, Mizuho
Ishiguro, Takahiro
Kishishita, Shohei
Sawada, Noriaki
Endo, Mika
Nezu, Junichi
CANCER RESEARCH, 2019, 79 (13)
[19] JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
Fontan, Lorena
Zwolak, Adam
Guimerans-Lorenzo, Irene
Bekkers, Mariette
Hein, Nicholas
Vloemans, Nele
Trella, Emanuele
Smets, Tina
Cornelissen, Ivo
Assefa, Alemu
Verbist, Bie
Amorim, Ricardo
Seth, Pankaj
Dash, Ranjeet Prasad
Luistro, Leopoldo
Mattson, Bethany
Dragovich, Matthew A.
Hedvat, Michael
Moore, Gregory L.
Desjarlais, John R.
Kutlu, Olivia
Erhardt, Joseph
Philippar, Ulrike
BLOOD, 2024, 144 : 1408 - 1409
[20] A novel first-in-class common-gamma chain cytokine facilitates expansion of CD8+T cells and offers a superior cellular source for adoptive T-cell therapy
Banerjee, Anirban
Guo, Yizhan
Hein, Sarah
Krupnick, Alexander S.
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →